(Total Views: 515)
Posted On: 03/15/2022 6:57:16 PM
Post# of 154882
Here is the last para from the last and only PR that the webpage displays for investors.
"CytoDyn will keep shareholders and stakeholders informed on the Company’s progress in implementing its leadership transition plan as and when appropriate."
I find it to have the same enigmatic/evasive quality that used to mark most of PRs in the Age of Nader.
"as and when appropriate"? So perhaps there has been no progress in implementing the transition plan or there has been some progress but it's not yet appropriate to let us know about it. OK. Now how about some other types of progress? Anything new about our trials "as we focus on continuing the clinical progress of leronlimab" (SK)? Here is the problem IMO. This last and only PR articulates no intention to update investors on anything but "leadership transition."
"CytoDyn will keep shareholders and stakeholders informed on the Company’s progress in implementing its leadership transition plan as and when appropriate."
I find it to have the same enigmatic/evasive quality that used to mark most of PRs in the Age of Nader.
"as and when appropriate"? So perhaps there has been no progress in implementing the transition plan or there has been some progress but it's not yet appropriate to let us know about it. OK. Now how about some other types of progress? Anything new about our trials "as we focus on continuing the clinical progress of leronlimab" (SK)? Here is the problem IMO. This last and only PR articulates no intention to update investors on anything but "leadership transition."
(3)
(0)
Whatever happens, we have got
Le-Ron-Li-Mab, and they have not.
Le-Ron-Li-Mab, and they have not.
